The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
In this session from the SOHO Insider Community Oncology Brown Bag series, Luke Fletcher, MD, presents on an exploration of barriers and solutions for activating
The discussion also covers the study’s safety profile and the potential for these early-stage immunotherapies to achieve long-term curative results.
The oral combination is used with venetoclax for patients who are at least 75 years old or have other medical conditions that prevent the use of intensive chemotherapy.
The US Food and Drug Administration has granted accelerated approval to sonrotoclax, a BCL-2 inhibitor, for adults with relapsed or refractory mantle cell lymphoma after
The phase I/II study was conducted at 15 sites in the United States and Canada. A total of 30 adults with AML or MDS at high risk of relapse received trem-cel as well as maintenance gemtuzumab ozogamicin, a CD33-targeting antibody, post-transplant.
Pirtobrutinib resulted in an 82.5% objective response rate in patients with Waldenström macroglobulinemia, and the ORR was 81.0% in those who previously received a Bruton’s
To access the SOHO Career Center click the following link.
